Company intelligence / Profile preview
Outrun Therapeutics
Dundee, Scotland, United Kingdomoutruntx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Outrun Therapeutics is developing small molecule inhibitors targeting E3 ligases to stabilize proteins that are destabilized in certain diseases. Their lead program focuses on a small molecule inhibitor targeting an E3 ligase that destabilizes a tumor suppressor protein in hard-to-treat solid tumors. The company recently exited stealth mode with a $10 million seed financing round in April 2024.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Outrun Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Outrun Therapeutics.